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1. Introduction 
Alzheimer's disease (AD) is a chronic neurodegenerative disorder, which affects approximately 
10% of the population at age 65 and older. The pathology of AD is characterized by an increased 
deposition of amyloid-β peptide (Aβ) in the brain, and a progressive impairment of cognition and 
memory of affected individuals. Blood Brain Barrier (BBB) dysfunction is observed in all of the 
stages of AD, and may even precede neuron degeneration in AD brains (Hofman et al., 
1997, Iadecola, 2003, Ruitenberg et al., 2005, de la Torre, 2006, Girouard and Iadecola, 
2006, Deane and Zlokovic, 2007, Zlokovic, 2008, Bell and Zlokovic, 2009). During the early 
stages of AD, microvasculature deficiencies and hypertrophy of astrocytes are commonly 
observed (Farkas and Luiten, 2001, Borroni et al., 2002). Numerous in vivo andin vitro studies 
have demonstrated that the vascular deposition of Aβ induces oxidative stress in cerebral 
vasculature and astrocytes (Cai et al., 2003, Abramov and Duchen, 2005). Aβ-induced oxidative 
stress in cells, in turn, initiates a cascade of redox reactions leading to apoptosis and 
neurovascular inflammation (Emmanuelle et al., 1997, Suo et al., 1998, Tan et al., 1999, Xu et 
al., 2001, Yin et al., 2002, Hsu et al., 2007, Vukic et al., 2009) 
Aβ-induced oxidative stress is associated with overproduction of reactive oxygen species (ROS) 
(Park et al., 2005, Girouard and Iadecola, 2006, Callaghan et al., 2008, Park et al., 2008). ROS 
can be generated by several enzymatic systems, but there is evidence that the superoxide-
producing enzyme, NADPH oxidase, is a major source of ROS in CECs and astrocytes (Cai et 
al., 2003, Abramov and Duchen, 2005, Park et al., 2005, Qing et al., 2005, Park et al., 2008, Zhu 
et al., 2009). Although these studies demonstrate that Aβ mediates oxidative damage to 
astrocytes and CECs mainly through the activation of NADPH oxidase, how Aβ activates 
NADPH oxidase has yet to be elucidated. 
Aβ-induced cytotoxic effects are also associated with the activation of MAPK/ERK1/2 cascade 
and the phosphorylation of cytosolic phospholipase A2 (cPLA2) (Stephenson et al., 
1996, McDonald et al., 1998,Dineley et al., 2001, Moses et al., 2006, Zhu et al., 2006, Shelat et 
al., 2008, Young et al., 2009). The ERKs (extracellular-signal-regulated kinases) are widely 
expressed protein kinases, and part of a signal transduction system through which extracellular 
stimuli are transduced. Activation of ERKs occurs in response to growth factor stimulation, 
cytokines, virus infection, transforming agents, carcinogens, and after the activation of high-
affinity IgG receptors (McDonald et al., 1998). Phospholipases A2 (PLA2s) are ubiquitously 
distributed enzymes that catalyze the hydrolysis at the sn-2 position of phospholipids to produce 
lysophospholipids and release arachidonic acid (Murakami and Kudo, 2002, Sun et al., 2004). 
PLA2s are classified into three major families: calcium-dependent cytosolic PLA2 (cPLA2), 
secretory PLA2 (sPLA2) and calcium-independent PLA2 (iPLA2). cPLA2 has been implicated in 
diverse cellular responses such as mitogenesis, differentiation, inflammation and cytotoxicity, 
and overproduction of this enzyme is involved in many neurodegenerative diseases, including 
AD (Stephenson et al., 1996, Sun et al., 2007). 
Recent studies have indicated that the receptor for advanced glycation endproducts (RAGE) is a 
binding site for Aβ (Yan et al., 1996, Lue et al., 2001, Sasaki et al., 2001, Arancio et al., 
2004, Chaney et al., 2005). RAGE is a multi-ligand cell surface receptor which is normally 
expressed in brain endothelium and, at low levels, in microglia and neurons (Lue et al., 
2001, Sasaki et al., 2001, Zlokovic, 2008). However, in AD brains, RAGE expression is 
increased by several-fold in cerebral endothelial cells, astrocytes, microglia, and neurons (Lue et 
al., 2001, Sasaki et al., 2001). Aβ binding to RAGE has been demonstrated to regulate Aβ 
transport across BBB, upregulate pro-inflammatory cytokines and adhesion molecules in CECs, 
and contribute to the transport of Aβ from the cell surface into the intracellular space in cortical 
neurons (Giri et al., 2000, Lue et al., 2001, Takuma et al., 2009). Since RAGE has been 
postulated to function as a signal transducing cell surface receptor for Aβ, it is reasonable to 
hypothesize that binding of Aβ1–42 oligomers (Aβ42) to surface RAGE results in activating of 
NADPH oxidase to induce ROS generation, and activate downstream pathways, including 
phosphorylation of ERK1/2 and cPLA2. 
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2. Experimental Procedures 
2.1 Cell cultures and treatment 
Mouse bEnd3 line of cerebral endothelial cells (CECs) was purchased from Fisher Scientific. Rat 
primary cortical astrocytes were purchased from Invitrogen (Carlsbad, CA). Purity of astrocyte 
culture was verified by double immunostaining with astrocytic marker (primary mouse 
monoclonal antibody to S100, Abcam Inc, Cambridge, MA) and microglia marker (primary 
rabbit polyclonal to antibody Coronin 1a, Neuromics, Edina, MN). The purity of astrocytes 
obtained from Invitrogen is 100%. 
Aβ42 and scrambled sequence peptide (Aβ42–1) from American Peptide (Sunnyvale, CA) were 
prepared by diluting 5mM Aβ in DMSO to 100 μM in ice-cold culture Ham's medium, and 
sonicated. The oligomeric form of Aβ42 in cell culture was verified by Western blot analysis. 
Menadione (Sigma, St. Louis, MO) was dissolved in DMSO (1mg/ml) and then diluted in cell 
culture medium to final concentration of 50 μM; rabbit polyclonal antibody against RAGE 
(AbRAGE, Abcam Inc), the specific NADPH oxidase inhibitor, gp91ds-tat (AnaSpec, Fremont, 
CA), and ROS scavenger, Tiron (Sigma), were diluted in DMEM. Experimental groups: control 
(cells without any treatment); cells treated with 2 and 5 μM of Aβ42 for 1 and 2 hr; cells treated 
with AbRAGE for 4 hr; cells treated with AbRAGE followed by Aβ42 (5 μM for 2 hr) treatment; cells 
treated with gp91ds-tat (1 μM for 1 hr) and tiron (5 mM for 1 hr) followed by Aβ42. Cells treated 
with menadione (50 μM for 30 min) and Aβ42–1 (5 μM for 2 hr) served as a positive and negative 
controls. 
2.2 Immunofluorescent staining for RAGE 
Cells were grown on cover slips until confluence. After treatment with Aβ42 (2 and 5 μM for 1 
hr), cells were fixed immediately using 3.7% paraformaldehyde solution for 30 min. To block 
non-specific binding, 5% sheep serum in PBS was applied to the cells for 1 hr. RAGE at the cell 
surface was labeled with its primary antibody (Abcam) without permeabilization at 4°C 
overnight, followed by sheep secondary antibody (Abcam) labeling at 25°C for 1 hr. To confirm 
the specificity of the primary antibodies, cells were labeled by secondary antibodies alone. 
Secondary antibodies did not show immunostaining in the absence of the primary antibody. 
2.3 Measurement of ROS production 
DHE (dihydroethidium) staining was applied to determine superoxide anion production (Zanetti 
et al., 2005). DHE reacts with O•-2 to produce oxyethidium (oxy-E), a highly fluorescent product, 
which binds to DNA and causes an increased fluorescent intensity in cell nuclei. For ROS 
measurements, cells were starved for 4 hr, rinsed twice with warm phenol free DMEM, and 
incubated with DHE (20μM) for 2 hr. 
2.4 Quantitative Immunofluorescence microscopy (QIM) 
Bright-field illumination and fluorescence microscopy were performed with Nikon TE-2000 U 
fluorescence microscope and 40X, NA 0.95 objective. Images were acquired using a cooled 
CCD camera controlled with a computer and uses MetaView imaging software. The typical 
exposure time for fluorescence image acquisition was 400 msec. Background was subtracted for 
all images prior to analysis. Relative expression of RAGE was quantified by calculating the 
intensity of secondary antibody fluorescence per cell. The intensity was then normalized by the 
control cells (without any treatment). A similar approach was applied to quantify the oxy-E 
fluorescence. 
2.5 Double immunofluorescent labeling of gp91-phox and p47-phox 
Cells were grown on cover slips until confluence. After treatment cells were fixed immediately 
using 3.7% paraformaldehyde solution for 30 min. To block non-specific binding, 5% mixture of 
sheep and donkey serum in PBS was applied to the cells for 1 hr. Plasma membrane gp91-phox 
was labeled with its primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) without 
permeabilization at 4°C overnight. For p47-phox labeling, cells were permeabilzed by 0.1% 
Triton X-100 in PBS for 5 min and labeled with its primary antibody (Santa Cruz 
Biotechnology) at 4°C overnight, followed by sheep and donkey polyclonal secondary antibodies 
(Abcam) labeling at room temperature for 1 hr. The emission spectra of the secondary antibodies 
were 528 nm (for gp91-phox) and 620 nm (for p47-phox). To confirm the specificity of the 
primary antibodies, cells were labeled by secondary antibodies alone. Secondary antibodies did 
not show immunostaining in the absence of the primary antibody. 
2.6 Confocal immunofluorescence microscopy 
Confocal immunofluorescence microscopy was performed with Olympus FV1000 confocal 
microscope. Confocal images were acquired with a 60 X, numerical aperture 1.2 oil immersion 
objective lens for colocalization studies of the cellular surface gp91-phox and p47-phox. The 
colocalization images were obtained by suppressing all colors, except yellow, in superimposed 
images using Matlab and Adobe Photoshop. A z-series at 1 μm intervals were captured to 
determine the spatial co-localization characteristics of gp91-phox or p47-phox staining within 
individual cells. The colocalization (the area of coincident intensity) between two channels was 
quantified by normalizing the coincident intensity (yellow) to the total intensity of the 
corresponding channel. 
2.7 Western blot analysis 
Following the treatments, primary astrocytes and CECs were harvested in 300 μL sample buffer 
containing 50 mM Tris-HCl, pH 7.4 1 mM EDTA, 100 mM NaCl, 0.1% sodium dodecyl sulfate, 
1 mM phenylmethylsulfonyl fluoride, 1mM sodium o-vanadate, 1μg/mL leupeptin, 1 μg/mL 
pepstatin, and 10 μg/mL aprotinin. Lysates were collected, sonicated, and equivalent amounts of 
each sample (40 μL) were resolved in 11.55% Tris-HCl gel electrophoresis. After 
electrophoresis, proteins were transferred to nitrocellulose membranes. Membranes were 
incubated in Tris-buffered saline, pH 7.4, with 0.5% Tween 20 (TBS-T) containing 5% non-fat 
milk for 1 hr at room temperature. The blots were then washed and reacted with either rabbit 
anti-phospho-cPLA2 (1:600; Cell Signaling Technology, Boston, MA) or rabbit anti-
cPLA2 (1:600; Cell Signaling Technology) or mouse anti-phospho-ERK1/2 (1:4000, Cell 
Signaling Technology) and rabbit anti-ERK1/2 (1:500; Cell Signaling Technology) overnight at 
4°C. After washing with TBS-T, they were incubated with goat anti-rabbit and goat anti-mouse 
IgG – horseradish peroxidase (1:5000; Santa Cruz) for 1 hr at room temperature. The blots then 
were washed 3 times with TBS-T. Immunolabeling was detected by chemiluminescence 
(SuperSignal West Pico and West Fempto). For quantification, blots were scanned and intensity 
of protein bands was measured as optical density using the Quantity One program (BioRAD, 
Hercules, CA, USA). Phospho-ERK1/2 and ERK1/2 were detected at 42/44 kDa, and phospho-
cPLA2 and cPLA2 were detected at 110 kDa. Ratios of phospho- ERK1/2 to ERK1/2 and 
phospho-cPLA2 to cPLA2 were calculated for each sample and normalized to the control. 
2.8 Statistical analysis 
Data from at least three independent experiments are reported as mean ± SD. Mean differences 
between experimental groups were tested with unpaired t-test. Values were considered 
significantly different at the p ≤ 0.05 level. Statistical analyses were performed on the Sigma Plot 
8.0 software. 
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3. Results 
3.1 Oligomeric Aβ42 interacts with the RAGE 
It has been reported that the binding of soluble Aβ to soluble RAGE inhibits further aggregation 
of Aβ peptides, while membrane bound RAGE-Aβ interactions elicit activation of the NF-κB 
transcription factor and promote sustained chronic neuroinflamation (Chaney et al., 2005). To 
further provide evidence of the Aβ42-RAGE binding, we examined with the immunofluorescence 
microscopy of RAGE for primary astrocytes and CECs pretreated with 2 and 5 μM of oligomeric 
Aβ42 at 37°C and 4°C (in which condition the internalization of surface receptors is suppressed). 
A lower fluorescent intensity of labeled RAGE was observed for cells pretreated with oligomeric 
Aβ42 in both temperature conditions (Fig. 1), suggesting that Aβ42 oligomers compete with 
AbRAGE to bind to RAGE at the surface of the astrocytes as well as CECs. 
 
Fig.1 
Oligomeric Aβ42 reduced the fluorescent intensity of RAGE staining at the primary 
astrocytes and CECs surface 
3.2 Polyclonal antibody to RAGE and NADPH inhibitor suppress Aβ42-induced ROS 
production in astrocytes and CECs 
To investigate ROS production in cells, we applied fluorescent microscopy of DHE, which reacts 
with O•-2to produce oxyethidium (oxy-E) with a higher quantum yield. Fig. 2 shows the images 
of DHE-stained CECs (A) and astrocytes (B) treated with Aβ42 oligomers, Aβ42-1, AbRAGE, ROS 
scavenger (tiron), and NADPH oxidase inhibitor (gp91ds-tat). Quantitative analysis was 
accomplished by integration of fluorescent intensity for each cell. Fig. 2 C, D show that 5 μM of 
Aβ42 increased DHE fluorescence in both primary astrocytes as well as in CECs by ~ 75% as 
compared to the control. Since menadione has been reported previously to induce ROS 
generation in astrocytes (Zhu et al., 2009), results from the treatment of menadione served as a 
positive control (Fig. 2A, C). As a negative control, reversed Aβ42-1 did not increase ROS 
generation. At the same time, Aβ42 stimulated ROS production in CECs and astrocytes was 
attenuated by blocking the cell surface RAGE with its antibody (Fig. A, C), or by the 
pretreatment with gp91ds-tat, the specific NADPH oxidase inhibitor (Fig. B, D). AbRAGE, or the 
inhibitor alone had no effect on DHE intensity. As a control, scrambled sequence peptide sr-
gp91ds-tat (sr-gp) did not suppress Aβ42-induced ROS overproduction. To verify this technique 
of measurement for superoxide anions, we demonstrated that ROS scavenger suppressed an 
Aβ42-mediated increase in DHE intensity. This data suggest that Aβ42 oligomers induce ROS 
production through their binding to RAGE leading to NADPH oxidase activation. 
 
Fig.2 
Representative images of dihydroethidium (DHE)-stained CECs (A) and astrocytes (B) 
treated with Aβ42 oligomers, polyclonal antibody to RAGE (AbRAGE), ROS scavenger (tiron), 
and NADPH oxidase inhibitor (gp91 ds_tat). Relative DHE fluorescent intensity ... 
3.3 Polyclonal antibody to RAGE suppresses Aβ42-induced colocalization of cytosolic subunit 
p47-phox of NADPH oxidase with its membrane subunits gp91-phox 
AbRAGE as well as NADPH oxidase inhibitor suppressed Aβ42-induced ROS production in CECs 
and astrocytes (Fig. 2C, D). NADPH oxidase is a membrane-bound enzyme that catalyzes the 
production of ROS from oxygen and NADPH. NADPH oxidase is a complex system consisting 
of two membrane-bound elements (gp91-phox and p22-phox), three cytosolic components (p67-
phox, p47-phox and p40-phox), and a low-molecular-weight G protein (Babior, 1999). 
Activation of NADPH oxidase is associated with the migration of the cytosolic components to 
the cell membrane and assembling with its membrane subunits. To confirm the role of Aβ42-
RAGE interactions in NADPH oxidase activation and subsequent ROS generation, we quantified 
the effect of Aβ42 and AbRAGE on the colocalization of p47-phox with gp91-phox by analyzing 
confocal images of double immunofluorescent-labeled gp91-phox and p47-phox in astrocytes 
and CECs (Fig. 3 A,B). Our results indicate that Aβ42 significantly increased the colocalization of 
cytosolic subunit p47-phox of NADPH oxidase with its membrane subunits gp91-phox, 
suggesting that Aβ42 enhances NADPH oxidase complex assembling. At the same time, pre-
treatment with AbRAGEsignificantly suppressed the colocalization of p47-phox with gp91-phox 
induced by Aβ42. To validate the fluorescent confocal microscopy method for measurement of 
the colocalization between these two subunits, we demonstrated that NADPH oxidase inhibitor 
(gp91ds-tat) suppressed Aβ42-mediated increase in colocalization (Fig. 3 A,B). The inhibitor 
alone, as well as AbRAGE, had no effect on the colocalization. This data indicated that 
Aβ42 oligomers induced colocalization of cytosolic subunit p47-phox of NADPH oxidase with its 
membrane subunits gp91-phox and subsequent ROS generation through binding to RAGE. 
 
Fig.3 
Polyclonal antibody to RAGE and NADPH oxidase inhibitor suppressed Aβ42 induced 
colocalization of p47-phox to gp91-phox 
3.4 Polyclonal antibody to RAGE inhibit Aβ42-induced phosphorylation ERK1/2 and cPLA2 in 
primary astrocytes and CECs 
Aβ42 has been shown to induce MAPK/ERK downstream signaling pathways, including the 
activation of extracellular-signal-regulated kinases (ERK), which further leads to 
phosphorylation of cPLA2(Emmanuelle et al., 1997, Xu et al., 2001, Yin et al., 2002, Hsu et al., 
2007, Shelat et al., 2008). Here, we tested if Aβ42 binding to RAGE induced ERK1/2 activation 
and phosphorylation of cPLA2 in CEC and astrocytes. Fig. 4 shows that Aβ42 significantly 
increased phosphorylation of ERK1/2 and cPLA2 in astrocytes and CECs, which were 
suppressed by the pretreatment with AbRAGE. Additionally, AbRAGEalone had no effect on 
phosphorylation of ERK1/2 and cPLA2 in both cell types. Our data suggested that Aβ42 binding 
to RAGE is required for the activation of ERK1/2 and further phosphorylation of cPLA2induced 
by Aβ42. 
 
Fig.4 
Polyclonal antibody to RAGE inhibits ERK1/2 and cPLA2α phosphorylation in primary 
astrocytes and CECs 
3.5 Effects of NADPH oxidase inhibitor and ROS scavenger on ERK1/2 and 
cPLA2 phosphorylation in CECs and primary astrocytes 
ROS from NADPH oxidase has been shown to induce the activation of ERK1/2 and 
phosphorylation of cPLA2 in primary neurons (Shelat et al., 2008). Our data suggest that 
Aβ42 oligomers induce ROS production through binding to RAGE which activates NADPH 
oxidase, and thus blocking cell surface RAGE with its antibody suppresses Aβ-induced 
phosphorylation of ERK1/2 and cPLA2 in CECs and primary astrocytes. Therefore, we 
hypothesized that Aβ42 binding to RAGE induces phosphorylation of ERK1/2 and cPLA2 through 
activation of NADPH oxidase and ROS production. 
In support of our hypothesis, Fig. 5 B,C,E,F show that pretreatment of CECs with NADPH 
oxidase inhibitor or ROS scavenger could significantly suppress Aβ42-induced phosphorylation 
of ERK1/2 and cPLA2. Surprisingly, only AbRAGE, but neither NADPH oxidase inhibitor nor ROS 
scavenger, inhibited Aβ42-induced ERK1/2 and cPLA2 phosphorylation in primary astrocytes 
(Fig. 4 A,B and Fig.5 A,C,D,F). NADPH oxidase inhibitor alone, as well as ROS scavenger, had 
no effect on phosphorylation of ERK1/2 and cPLA2 in both cell types (Fig. 3.5 A–F). 
 
Fig.5 
Effects of NADPH oxidase inhibitor and ROS scavenger on ERK1/2 and cPLA2α 
phosphorylation in primary astrocytes and CECs 
These data suggest a presence of two different downstream pathways in the CECs and astrocytes. 
Although Aβ42 binding to RAGE is required to induce phosphorylation of ERK1/2 and cPLA2 in 
both CECs and primary astrocytes, NADPH oxidase inhibition does not suppress 
phosphorylation of ERK1/2 and cPLA2in primary astrocytes. 
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4. Discussion 
Results from this study provided support for the involvement of RAGE in Aβ42-mediated 
oxidative stress and downstream MAPK/ERK pathway in CECs and astrocytes. Specifically, we 
demonstrated that Aβ42oligomers directly bind to RAGE at the surface of the cells to induce 
colocalization between NADPH oxidase subunits gp91-phox and p47-phox, and subsequently 
leading to generation of ROS, and phosphorylation of ERK1/2 and cPLA2 in CECs. 
Interestingly, our data also showed that activation of NADPH oxidase and increased ROS 
production were not required for Aβ-induced phosphorylation of ERK1/2 and cPLA2 in 
astrocytes. 
In agreement with impairments of BBB structure and functions in AD, many studies have 
indicated a decrease in cerebral blood flow, reduced microvascular density, and low 
immunoreactivity of endothelial markers CD34 and CD31 in AD brains (Kalaria and Pax, 
1995, Luc et al., 1997, Berzin et al., 2000, Bailey et al., 2004, Ervin et al., 2004). Although there 
is evidence that oxidative stress is a major factor leading to a BBB cells dysfunction in AD, the 
mechanism for production of Aβ-induced ROS has not been clearly elucidated (Smith et al., 
1991, Behl et al., 1994, Mecocci et al., 1994, Cini and Moretti, 1995, Simonian and Coyle, 
1996, Behl and Holsboer, 1998, Heneka and O'Banion, 2007). Recently, RAGE has been 
postulated to function as a signal transducing cell surface acceptor for Aβ (Yan et al., 1996, Lue 
et al., 2001, Sasaki et al., 2001, Arancio et al., 2004, Chaney et al., 2005). In fact, the possible 
links between RAGE and oxidative stress has been reported (Yan et al., 1996, Lue et al., 
2001, Sasaki et al., 2001,Arancio et al., 2004, Chaney et al., 2005). ROS has been demonstrated 
to be generated by the advanced glycation end products (AGE)-RAGE interaction in human 
endothelial cells (Wautier et al., 2001). Inhibition studies have indicated that anti-RAGE IgG 
significantly suppressed oxidative stress induced by Aβ both in vascular and neuronal cell (Yan 
et al., 1996); however, the relationship between Aβ-RAGE interactions and NADPH oxidase has 
yet to be elucidated. 
It is suggested that NADPH oxidase is the primary source of superoxide in astrocytes and CECs 
(Cai et al., 2003, Abramov and Duchen, 2005, Park et al., 2005, Qing et al., 2005, Park et al., 
2008, Zhu et al., 2009). We have previously reported that Aβ42 oligomers induce ROS generation 
through activation of NADPH oxidase in primary astrocytes (Zhu et al., 2006). It has been 
shown that inhibition of NADPH oxidase significantly suppressed ROS released in rat astrocytes 
(Qing et al., 2005). Aβ-induced ROS overproduction and mitochondrial depolarization were 
absent in astrocytes cultured from gp91phox knockout transgenic mice (Abramov and Duchen, 
2005). In a model of AD, inhibition of NADPH oxidase has been found to abrogate Aβ-induced 
ROS production and alteration of cerebrovascular functions (Park et al., 2005). APP transgenic 
mice lacking the NADPH oxidase subunits gp91-phox or phagocytic NADPH oxidase (Nox2) 
did not develop oxidative stress, cerebrovascular dysfunction, and behavioral deficits (Park et al., 
2005, Park et al., 2008). Our results suggest that Aβ42 oligomers induce ROS production through 
binding to RAGE and activation of NADPH oxidase (Fig. 2, ,33). 
Aβ-induced ROS generation, in turn, triggers the downstream pathway of cPLA2 (Shelat et al., 
2008). It has been reported that the immunoreactivity of cPLA2 (group IVA) increased in 
reactive astrocytes in severe AD brains (Stephenson et al., 1996, 1999). In vitro, treatment of 
astrocytes with Aβ increased ROS production from NADPH oxidase and activated cPLA2 (Zhu 
et al., 2006, Hicks et al., 2008). Furthermore, cPLA2 was shown to cause a decrease in 
mitochondrial membrane potential (Δψm) and resulted in more ROS production (Zhu et al., 
2006). In primary rat cortical astrocytes, menadione induced ROS production mediated by 
NADPH oxidase (Zhu et al., 2009). In neurons, Aβ-induced ROS generation led to 
phosphorylation of cPLA2 and arachidonic acid (AA) release (Shelat et al., 2008). In turn, 
hydrolytic products of cPLA2 was shown to enhance NADPH oxidase activity, forming a viscous 
cycle (Cherny et al., 2001, Levy, 2006). Our data showed that Aβ42 induced phosporylation of 
cPLA2 was totally suppressed by AbRAGE (Fig.4), suggesting the involvement of RAGE in this 
signaling pathway. 
There are several cell-specific mechanisms identified for activation of cPLA2. In primary 
astrocytes, phosphorylation of cytosolic cPLA2 and the subsequent release of AA can be 
activated by G-protein-coupled receptor agonists (Yin et al., 2002, Sun et al., 2007). In cortical 
neurons, protein kinase C (PKC), extracellular signal-regulated kinases (ERK1/2), and p38 
mitogen-activated protein kinase have been involved in activation of cPLA2 and ROS production 
(Sun et al., 2007). In turn, there is a link between Aβ, RAGE, and MAPKs. Several studies have 
indicated that Aβ induced apoptosis signal-regulating kinase 1 (ASK1) dephosphorylation and 
p38 MAPK activation in CECs (Emmanuelle et al., 1997, Xu et al., 2001,Yin et al., 2002, Hsu et 
al., 2007). Similarly, stimulation of RAGE has also been demonstrated to mediate alterations in 
the phosphorylation state of MAPKs (Origlia et al., 2009). Our data provided a link between 
these studies and demonstrated that binding of Aβ42 to RAGE mediated alterations in the 
phosphorylation state of ERK1/2 and cPLA2 both in primary astrocytes as well as in CECs 
(Fig.4). 
Although Aβ42 binding to RAGE is required to induce phosphorylation of ERK1/2 and cPLA2 in 
both cell types, we found the existence of two slightly different downstream pathways for CECs 
and astrocytes. In CECs, NADPH oxidase inhibitor gp91ds-tat and ROS scavenger Tiron 
attenuated Aβ42-induced ROS production, ERK1/2 activation, and cPLA2 phosphorylation (Fig. 5 
B,C,E,F). In primary astrocytes, inhibition of NADPH oxidase and ROS production did not 
suppress Aβ42-induced ERK1/2 and cPLA2phosphorylation (Fig.5 A,C,D,F). Apparently, results 
here are not in agreement with our previous studies showing Aβ42-induced ERK1/2 and 
cPLA2 phosphorylation in astrocytes through NADPH oxidase (Zhu et al., 2006, Zhu et al., 
2009). One possible explanation is differences in use of NADPH oxidase inhibitors. In the study 
by Zhu et al., apocynin was used as NADPH oxidase inhibitor. Several studies indicate that 
apocynin can inhibit NADPH oxidase only in blood derived cells (leukocytes, microglia, etc) 
(Heumuller et al., 2008), and in other cell types, this compound can act as an antioxidant 
(Heumuller et al., 2008). In fact, in other cases, apocynin can even exert as an oxidant (Riganti et 
al., 2006). These results suggest that effects of apocynin may different depending on 
experimental conditions, and thus should be interpreted with caution. In our study, we used 
gp91ds-tat which is a specific NADPH oxidase inhibitor. Differences in effects of NADPH 
oxidase inhibition on ERK1/2 and cPLA2 phosphorylation could also result from the preparation 
of astrocytes and the purity of the cell culture. Therefore, more investigations are required to 
unravel the mechanism(s) underlying the Aβ-RAGE interaction resulting in activations of 
ERK1/2 and cPLA2 in astrocytes. 
In summary, this study demonstrates the important role of Aβ42-RAGE interaction for NADPH 
oxidase complex assembling, resulting in subsequent ROS generation, activation of MAPK/ERK 
pathway, and the phosphorylation of cPLA2 in CECs and primary astrocytes. Our results also 
revealed two possibly different RAGE-dependent signal transducing pathways in CECs and 
astrocytes. In CEC, it is possible to demonstrate requirement for NADPH oxidase-mediated 
generation of ROS to activate ERK1/2 and cPLA2, whereas, astrocytes may activate ERK1/2 and 
cPLA2 independent of NADPH oxidase. Understanding the precise molecular mechanisms 
underlying Aβ-mediated oxidative stress should prove to provide new insights into the 
development of preventive and treatment strategies for AD. 
 
*Highlights 
 > Aβ binding to RAGE to activate NADPH oxidase in endothelial cells and astrocytes. 
 > Aβ binding to RAGE to activate cPLA2 in endothelial cells and astrocytes. 
 > NADPH oxidase activation is not needed for Aβ to activate cPLA2 in astrocytes. 
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